| Total Revenue Growth1 |
17% to 24% |
| Galafold Revenue Growth1 |
10% to 15% |
| Pombiliti + Opfolda Growth1 |
65% to 85% |
| Gross Margin |
Mid 80% |
| Non-GAAP Operating Expenses4 |
$350M to $370M |
| GAAP Net Income |
Positive during H2 2025 |
More on Amicus Therapeutics
- Amicus Therapeutics: Cheap Heading Into 2025
- Amicus Therapeutics FY 2024 Earnings Preview
- Amicus Therapeutics expects 2024 revenue slightly above consensus, guides 2025
- Seeking Alpha’s Quant Rating on Amicus Therapeutics
- Historical earnings data for Amicus Therapeutics